Please use this identifier to cite or link to this item:
Title: Transfusion-transmitted hepatitis E: What we know so far?
Authors: Cheung, Carmen Ka Man
Wong, Sunny Hei
Law, Alvin Wing Hin
Law, Man Fai
Keywords: Science::Medicine
Issue Date: 2022
Source: Cheung, C. K. M., Wong, S. H., Law, A. W. H. & Law, M. F. (2022). Transfusion-transmitted hepatitis E: What we know so far?. World Journal of Gastroenterology, 28(1), 47-75.
Journal: World Journal of Gastroenterology
Abstract: Hepatitis E virus (HEV) is a major cause of viral hepatitis globally. There is growing concern about transfusion-transmitted HEV (TT-HEV) as an emerging global health problem. HEV can potentially result in chronic infection in immunocompromised patients, leading to a higher risk of liver cirrhosis and even death. Between 0.0013% and 0.281% of asymptomatic blood donors around the world have HEV viremia, and 0.27% to 60.5% have anti-HEV immunoglobulin G. HEV is infectious even at very low blood concentrations of the virus. Immunosuppressed patients who develop persistent hepatitis E infection should have their immunosuppressant regimen reduced; ribavirin may be considered as treatment. Pegylated interferon can be considered in those who are refractory or intolerant to ribavirin. Sofosbuvir, a nucleotide analog, showed modest antiviral activity in some clinical studies but sustained viral response was not achieved. Therefore, rescue treatment remains an unmet need. The need for HEV screening of all blood donations remains controversial. Universal screening has been adopted in some countries after consideration of risk and resource availability. Various pathogen reduction methods have also been proposed to reduce the risk of TT-HEV. Future studies are needed to define the incidence of transmission through transfusion, their clinical features, outcomes and prognosis.
ISSN: 1007-9327
DOI: 10.3748/wjg.v28.i1.47
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2022 The Authors. Published by Baishideng Publishing Group Inc. All rights reserved. This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
WJG-28-47.pdf747.64 kBAdobe PDFThumbnail

Citations 20

Updated on Sep 22, 2023

Web of ScienceTM
Citations 20

Updated on Sep 20, 2023

Page view(s)

Updated on Sep 23, 2023

Download(s) 50

Updated on Sep 23, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.